AZRX insider filings

AzurRx BioPharma, Inc. — 9 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-09-13. Screen AZRX transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for AZRX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — AzurRx BioPharma, Inc.

FiledFormInsiderReported transactionsSource
2021-09-134Coelho Mary Theresa — DirectorGrant/award (A): 10,310 (derivative) @ $0EDGAR
2021-07-094Pennington James — CHIEF MEDICAL OFFICERGrant/award (A): 100,000 (derivative) @ $0EDGAR
2021-07-024Schneiderman Daniel H — CHIEF FINANCIAL OFFICEROther (J): 35,006 (derivative) @ $0 · Grant/award (A): 35,006 (derivative) @ $0 · Other (J): 250,000 (derivative) @ $0 · Grant/award (A): 250,000 (derivative) @ $0EDGAR
2021-07-024SAPIRSTEIN JAMES — PRES, CEO & CHAIRMAN OF BOARD, DirectorOther (J): 900,000 (derivative) @ $0 · Grant/award (A): 900,000 (derivative) @ $0EDGAR
2021-01-064Oakes Gregory — DirectorGrant/award (A): 41,237 (derivative) @ $0EDGAR
2021-01-064Schramm Vern Lee — DirectorGrant/award (A): 41,237 (derivative) @ $0EDGAR
2021-01-064Riddell Alastair — DirectorGrant/award (A): 41,237 (derivative) @ $0EDGAR
2021-01-064BORKOWSKI EDWARD — DirectorGrant/award (A): 41,237 (derivative) @ $0EDGAR
2021-01-064CASAMENTO CHARLES J — DirectorGrant/award (A): 41,237 (derivative) @ $0EDGAR

Recent 8-K events — AzurRx BioPharma, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-178-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
3.02 — Unregistered Sales of Equity Securities
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-308-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-288-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-288-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-238-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2026-10-078-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-118-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-238-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-078-K/A1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
EDGAR
2026-07-068-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits
EDGAR

Registration filings — AzurRx BioPharma, Inc.

Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=AZRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs